Yvonne Yu-Hsuan Chen

Professor, MIMG, University of California Los Angeles

(310) 825-2816

Education and Training

Harvard Medical SchoolPostdoc06/2013Systems Biology
California Institute of TechnologyPhD12/2010Chemical Engineering
Stanford UniversityBS06/2004Chemical Engineering


  1. Lin MY, Nam E, Shih RM, Shafer A, Bouren A, Ayala Ceja M, Harris C, Khericha M, Vo KH, Kim M, Tseng CH, Chen YY. Self-regulating CAR-T cells modulate cytokine release syndrome in adoptive T-cell therapy.. The Journal of experimental medicine, 2024.
  2. Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies.. The Journal of experimental medicine, 2024.
  3. Hong M, Talluri S, Chen YY. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors.. Current opinion in biotechnology, 2023.
  4. Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy.. Gene therapy, 2023.
  5. Clubb JD, Gao TA, Chen YY. Synthetic Biology in the Engineering of CAR-T and CAR-NK Cell Therapies: Facts and Hopes.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2023.
  6. Lakhani A, Chen X, Chen LC, Khericha M, Chen YY, Park JO. Extracellular Domains of CAR Reprogram T-Cell Metabolism Without Antigen Stimulation.. bioRxiv : the preprint server for biology, 2023.
  7. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, Chen JM, Roshandell M, Harris C, Khericha M, Schweppe T, Berent-Maoz B, Gosliner SB, Almaktari A, Ceja MA, Allen-Auerbach MS, Said J, Nawaly K, Mead M, de Vos S, Young PA, Oliai C, Schiller GJ, Timmerman JM, Ribas A, Chen YY. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.. Cancer discovery, 2023.
  8. Chen X, Chen LC, Khericha M, Meng X, Salvestrini E, Shafer A, Iyer N, Alag AS, Ding Y, Nicolaou DM, Chen YY. Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR.. Cancer immunology research, 2023.
  9. Cabrera A, Edelstein HI, Glykofrydis F, Love KS, Palacios S, Tycko J, Zhang M, Lensch S, Shields CE, Livingston M, Weiss R, Zhao H, Haynes KA, Morsut L, Chen YY, Khalil AS, Wong WW, Collins JJ, Rosser SJ, Polizzi K, Elowitz MB, Fussenegger M, Hilton IB, Leonard JN, Bintu L, Galloway KE, Deans TL. The sound of silence: Transgene silencing in mammalian cell engineering.. Cell systems, 2022.
  10. Gao TA, Chen YY. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.. Annual review of chemical and biomolecular engineering, 2022.
  11. Gao TA, Chen YY. T cells to fix a broken heart.. Science (New York, N.Y.), 2022.
  12. Shih RM, Chen YY. Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy.. Cancer immunology research, 2022.
  13. Hong M, Chen YY. Killer fatigue: Transition to NK-cell-like phenotype is a signature of CAR-T cell exhaustion.. Cell, 2021.
  14. Chen LC, Hou AJ, Chen YY. Getting better mileage with logically primed CARs.. Med (New York, N.Y.), 2021.
  15. Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment.. Nature reviews. Drug discovery, 2021.
  16. Chen YY, Lim W, Levings M, Blazar B, Krenciute G, Wong W, Lehner M. What is the Optimal Design-Build-Test Cycle for Clinically Relevant Synthetic CAR T Cell Therapies?. Cell systems, 2020.
  17. Li JH, Chen YY. A Fresh Approach to Targeting Aging Cells: CAR-T Cells Enhance Senolytic Specificity.. Cell stem cell, 2020.
  18. Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY, Zhao W. CAR-T design: Elements and their synergistic function.. EBioMedicine, 2020.
  19. Hong M, Clubb JD, Chen YY. Engineering CAR-T Cells for Next-Generation Cancer Therapy.. Cancer cell, 2020.
  20. Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, Wang X, Brown CE, Chen YY. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.. Nature communications, 2020.
  21. Chang ZL, Hou AJ, Chen YY. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands.. Nature protocols, 2020.
  22. Chen YY, Van Deventer JA. Editorial overview: Pharmaceutical biotechnology: new frontiers in protein, gene, and cell therapies.. Current opinion in biotechnology, 2019.
  23. Chen YY. Cell fishing with DNA aptamers.. Nature biomedical engineering, 2019.
  24. Chen LC, Chen YY. Outsmarting and outmuscling cancer cells with synthetic and systems immunology.. Current opinion in biotechnology, 2019.
  25. Hou AJ, Chang ZL, Lorenzini MH, Zah E, Chen YY. TGF-β-responsive CAR-T cells promote anti-tumor immune function.. Bioengineering & translational medicine, 2018.
  26. Katz L, Chen YY, Gonzalez R, Peterson TC, Zhao H, Baltz RH. Synthetic biology advances and applications in the biotechnology industry: a perspective.. Journal of industrial microbiology & biotechnology, 2018.
  27. Chen YY. Increasing T Cell Versatility with SUPRA CARs.. Cell, 2018.
  28. Chang ZL, Lorenzini MH, Chen X, Tran U, Bangayan NJ, Chen YY. Rewiring T-cell responses to soluble factors with chimeric antigen receptors.. Nature chemical biology, 2018.
  29. Ho P, Chen YY. Mammalian synthetic biology in the age of genome editing and personalized medicine.. Current opinion in chemical biology, 2017.
  30. Ho P, Ede C, Chen YY. Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity.. ACS synthetic biology, 2017.
  31. Chang ZL, Chen YY. CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.. Trends in molecular medicine, 2017.
  32. Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. ADDENDUM: T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.. Cancer immunology research, 2016.
  33. Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.. Cancer immunology research, 2016.
  34. Ede C, Chen X, Lin MY, Chen YY. Quantitative Analyses of Core Promoters Enable Precise Engineering of Regulated Gene Expression in Mammalian Cells.. ACS synthetic biology, 2016.
  35. Chen YY. Efficient Gene Editing in Primary Human T Cells.. Trends in immunology, 2015.
  36. Chang ZL, Silver PA, Chen YY. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.. Journal of translational medicine, 2015.
  37. Chen YY, Galloway KE, Smolke CD. Synthetic biology: advancing biological frontiers by building synthetic systems.. Genome biology, 2012.
  38. Chen YY, Smolke CD. From DNA to targeted therapeutics: bringing synthetic biology to the clinic.. Science translational medicine, 2011.
  39. Beisel CL, Chen YY, Culler SJ, Hoff KG, Smolke CD. Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing.. Nucleic acids research, 2010.
  40. Chen YY, Jensen MC, Smolke CD. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems.. Proceedings of the National Academy of Sciences of the United States of America, 2010.